Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this four-year study, pediatric patients with inoperable plexiform neurofibromas and type 1 neurofibromatosis treated with selumetinib frequently experienced dermatologic side effects, which required tailored management strategies and sometimes led to treatment suspension, potentially affecting tumor regrowth.

This case report adds to the understanding of neurofibromatosis type 1 by documenting an Egyptian child with the condition alongside multiple unusual congenital anomalies, highlighting the importance of considering NF1 when these features are present.

This study observed that among children with neurofibromatosis type 1 in Russia, selumetinib treatment led to a partial reduction in plexiform neurofibroma volume in 65% of cases, with 56% showing a long-term response without surgery; common side effects included skin rash and hair issues.

This case report describes a rare co-existence of Becker nevus and plexiform neurofibroma in a child with genetically confirmed neurofibromatosis type 1, offering insights into the potential cellular and molecular links between these lesions.

In this case report, a 4-year-old with neurofibromatosis type 1 experienced significant reduction in an inoperable periorbital plexiform neurofibroma and visual improvement following treatment with selumetinib.